Mildred Felder

1.5k total citations
39 papers, 1.1k citations indexed

About

Mildred Felder is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Mildred Felder has authored 39 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Immunology, 13 papers in Molecular Biology and 11 papers in Oncology. Recurrent topics in Mildred Felder's work include Immune Cell Function and Interaction (14 papers), Immunotherapy and Immune Responses (14 papers) and Immune cells in cancer (7 papers). Mildred Felder is often cited by papers focused on Immune Cell Function and Interaction (14 papers), Immunotherapy and Immune Responses (14 papers) and Immune cells in cancer (7 papers). Mildred Felder collaborates with scholars based in United States, China and Chile. Mildred Felder's co-authors include Manish S. Patankar, Arvinder Kapur, Joseph P. Connor, Sachi Horibata, Paul M. Sondel, Kevin Hu, Hadi Shojaei, Lucas Fass, Joseph Heintz and Rebecca J. Whelan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

Mildred Felder

39 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mildred Felder United States 17 467 445 421 157 145 39 1.1k
Oliver Weigert Germany 20 178 0.4× 403 0.9× 657 1.6× 178 1.1× 107 0.7× 74 1.3k
Oliver Manzke Germany 19 676 1.4× 552 1.2× 627 1.5× 44 0.3× 100 0.7× 36 1.9k
E. Kutarska Poland 12 211 0.5× 274 0.6× 440 1.0× 66 0.4× 285 2.0× 17 939
Peter Ruf Germany 15 369 0.8× 323 0.7× 609 1.4× 40 0.3× 53 0.4× 30 998
A H Sarris United States 20 357 0.8× 294 0.7× 772 1.8× 42 0.3× 50 0.3× 46 1.6k
Huiying Piao United States 10 98 0.2× 715 1.6× 442 1.0× 168 1.1× 160 1.1× 10 1.2k
Jari Sundström Finland 22 154 0.3× 484 1.1× 520 1.2× 332 2.1× 95 0.7× 49 1.2k
Nagesh Kalakonda United Kingdom 17 153 0.3× 734 1.6× 544 1.3× 98 0.6× 35 0.2× 52 1.4k
Cristiana Carniti Italy 21 314 0.7× 396 0.9× 439 1.0× 116 0.7× 38 0.3× 59 1.2k
An Coosemans Belgium 21 545 1.2× 409 0.9× 523 1.2× 238 1.5× 502 3.5× 76 1.6k

Countries citing papers authored by Mildred Felder

Since Specialization
Citations

This map shows the geographic impact of Mildred Felder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mildred Felder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mildred Felder more than expected).

Fields of papers citing papers by Mildred Felder

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mildred Felder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mildred Felder. The network helps show where Mildred Felder may publish in the future.

Co-authorship network of co-authors of Mildred Felder

This figure shows the co-authorship network connecting the top 25 collaborators of Mildred Felder. A scholar is included among the top collaborators of Mildred Felder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mildred Felder. Mildred Felder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rakhmilevich, Alexander L., Mildred Felder, Amy K. Erbe, et al.. (2024). A combined radio-immunotherapy regimen eradicates late-stage tumors in mice. Frontiers in Immunology. 15. 1419773–1419773. 1 indexed citations
2.
Kapur, Arvinder, et al.. (2023). Oxidative phosphorylation inhibitors inhibit proliferation of endometriosis cells. Reproduction. 165(6). 617–628. 10 indexed citations
3.
Pieper, Alexander, Mildred Felder, Zachary S. Morris, et al.. (2023). Factors impacting the efficacy of the in-situ vaccine with CpG and OX40 agonist. Cancer Immunology Immunotherapy. 72(7). 2459–2471. 3 indexed citations
4.
Pieper, Alexander, Justin C. Jagodinsky, Mildred Felder, et al.. (2021). Radiation Augments the Local Anti-Tumor Effect of In Situ Vaccine With CpG-Oligodeoxynucleotides and Anti-OX40 in Immunologically Cold Tumor Models. Frontiers in Immunology. 12. 763888–763888. 15 indexed citations
5.
Felder, Mildred, Arvinder Kapur, Alexander L. Rakhmilevich, et al.. (2019). MUC16 suppresses human and murine innate immune responses. Gynecologic Oncology. 152(3). 618–628. 27 indexed citations
6.
Rakhmilevich, Alexander L., Mildred Felder, Hans Loibner, et al.. (2017). Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model. The Journal of Immunology. 198(4). 1575–1584. 16 indexed citations
7.
Shi, Yongyu, Mildred Felder, Paul M. Sondel, & Alexander L. Rakhmilevich. (2015). Synergy of anti-CD40, CpG and MPL in activation of mouse macrophages. Molecular Immunology. 66(2). 208–215. 16 indexed citations
8.
Meier, Christoph, et al.. (2014). The role of teriparatide in sequential and combination therapy of osteoporosis. Swiss Medical Weekly. 144(2324). w13952–w13952. 18 indexed citations
9.
Felder, Mildred, Arvinder Kapur, Jesús González Bosquet, et al.. (2014). MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Molecular Cancer. 13(1). 129–129. 379 indexed citations
10.
Ma, Di, Arvinder Kapur, Mildred Felder, et al.. (2013). Differential expression of proteins in naïve and IL-2 stimulated primary human NK cells identified by global proteomic analysis. Journal of Proteomics. 91. 151–163. 15 indexed citations
11.
Connor, Joseph P., Mihaela Cristea, Nancy Lewis, et al.. (2013). A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors. BMC Cancer. 13(1). 20–20. 35 indexed citations
12.
Felder, Mildred. (2012). The immunomodulating roles of glycoproteins in epithelial ovarian cancer. Frontiers in Bioscience-Elite. E4(2). 631–650. 2 indexed citations
13.
14.
Rakhmilevich, Alexander L., Mildred Felder, Richard K. Yang, et al.. (2012). Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects. Cancer Immunology Immunotherapy. 61(10). 1683–1697. 12 indexed citations
15.
16.
Kapur, Arvinder, Mildred Felder, Jennifer A. Belisle, et al.. (2012). The Mucin MUC16 (CA125) Binds to NK Cells and Monocytes from Peripheral Blood of Women with Healthy Pregnancy and Preeclampsia. American Journal of Reproductive Immunology. 68(1). 28–37. 24 indexed citations
17.
Ziebarth, Angela, Mildred Felder, Josephine Harter, & Joseph P. Connor. (2012). Uterine leiomyosarcoma diffusely express disialoganglioside GD2 and bind the therapeutic immunocytokine 14.18-IL2: implications for immunotherapy. Cancer Immunology Immunotherapy. 61(7). 1149–1153. 8 indexed citations
18.
Xiang, Xinran, Mingqian Feng, Mildred Felder, et al.. (2011). HN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy. Journal of Cancer. 2. 280–291. 30 indexed citations
19.
Buhtoiarov, Ilia N., et al.. (2010). Enhanced T-cell-independent Antitumor Effect of Cyclophosphamide Combined With Anti-CD40 mAb and CpG in Mice. Journal of Immunotherapy. 34(1). 76–84. 18 indexed citations
20.
Connor, Joseph P. & Mildred Felder. (2008). Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance. Gynecologic Oncology. 111(2). 330–335. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Oliver Weigert Breakdown of academic impact, for papers by Oliver Manzke Breakdown of academic impact, for papers by E. Kutarska Breakdown of academic impact, for papers by Peter Ruf Breakdown of academic impact, for papers by A H Sarris Breakdown of academic impact, for papers by Huiying Piao Breakdown of academic impact, for papers by Jari Sundström Breakdown of academic impact, for papers by Nagesh Kalakonda Breakdown of academic impact, for papers by Cristiana Carniti Breakdown of academic impact, for papers by An Coosemans
Rankless by CCL
2026